The Combination of Cyproterone Acetate and Low Dose Diethylstilbestrol in the Treatment of Advanced Prostatic Carcinoma-Reference-Cited by-同舟云学术

The Combination of Cyproterone Acetate and Low Dose Diethylstilbestrol in the Treatment of Advanced Prostatic Carcinoma

Published:1988-12 Issue:6 Volume:140 Page:1460-1465
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Goldenberg S. Larry¹,Bruchovsky Nicholas¹,Rennie Paul S.¹,Coppin Chris M.¹

Affiliation:

1. From the Department of Cancer Endocrinology, Division of Medical Oncology, Cancer Control Agency of British Columbia, and Division of Urology, University of British Columbia, Vancouver, Canada

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference29 articles.

1. Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma;Robinson;Brit. Med. J.,1971

2. Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer;Shearer;Brit. J. Urol.,1973

3. Bilateral orchiectomy for carcinoma of prostate. Responses of serum testosterone and clinical response to subsequent estrogen therapy;Klugo;Urology,1981

4. Mechanisms of action of androgens and antiandrogens: effects of antiandrogens on translocation of cytoplasmic androgen receptor and nuclear abundance of dihydrotestosterone;Callaway;Prostate,1982

5. Biological significance of measurable androgen levels in the rat ventral prostate following castration;Kyprianou;Prostate,1987

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Semaphorin 3C promotes de novo steroidogenesis in prostate cancer cells;Endocrine-Related Cancer;2023-10-06

2. A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers;Cells;2022-07-20

3. SEMA 3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1;EMBO Molecular Medicine;2018-01-18

4. Randomized phase 2 study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer;Cancer;2014-08-22

5. Co-targeting Adaptive Survival Pathways;Management of Castration Resistant Prostate Cancer;2014